Ipca Laboratories (NSEI:IPCALAB) - Prezzo delle azioni, notizie e analisi

IPCALAB Panoramica delle azioni

IPCALAB analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	4/6
Prestazioni passate	4/6
Salute finanziaria	5/6
Dividendi	4/6

Premi

Si prevede che gli utili cresceranno del 30.5% all'anno

Gli utili sono cresciuti del 34.3% nell'ultimo anno

Analisi del rischio

Andamento instabile dei dividendi

Ipca Laboratories Limited Concorrenti

Ajanta Pharma

NSEI:AJANTPHARM

₹360.8b

Gland Pharma

NSEI:GLAND

₹292.2b

GlaxoSmithKline Pharmaceuticals

BSE:500660

₹408.6b

J. B. Chemicals & Pharmaceuticals

BSE:506943

₹260.8b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Ipca Laboratories
Prezzi storici delle azioni
Prezzo attuale dell'azione	₹1,566.70
Massimo di 52 settimane	₹1,708.65
Minimo di 52 settimane	₹1,041.00
Beta	0.23
1Variazione di 1 mese	-5.04%
Variazione a 3 mesi	13.18%
Variazione di 1 anno	47.70%
3Variazione a 3 anni	54.22%
Variazione a 5 anni	184.40%
Variazione dall'IPO	4,022.89%

Notizie e aggiornamenti recenti

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Nov 17

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Sep 10

Recent updates

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Nov 17

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Sep 10

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Jun 07

These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Sep 20

Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Aug 09

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Jun 08

How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Mar 26

Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Mar 13

Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Feb 28

Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Feb 23

Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?

Feb 11

Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?

Jan 30

The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It

Jan 15

Rendimenti per gli azionisti

	IPCALAB	IN Pharmaceuticals	IN Mercato
7D	2.3%	-3.0%	-3.3%
1Y	47.7%	42.9%	27.5%

Ritorno vs Industria: IPCALAB ha superato il Indian Pharmaceuticals che ha restituito 42.9 % nell'ultimo anno.

Rendimento vs Mercato: IPCALAB ha superato il mercato Indian che ha restituito 27.5 % nell'ultimo anno.

Volatilità dei prezzi

Is IPCALAB's price volatile compared to industry and market?
IPCALAB volatility
IPCALAB Average Weekly Movement	3.7%
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	6.2%
10% most volatile stocks in IN Market	9.2%
10% least volatile stocks in IN Market	4.0%

Prezzo delle azioni stabile: IPCALAB non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 4% ) di IPCALAB è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1949	17,335	Pranay Godha	www.ipca.com

Ipca Laboratories Limited, azienda farmaceutica, produce e commercializza formulazioni e ingredienti farmaceutici attivi (API) per vari segmenti terapeutici in India, Europa, Africa, Americhe, Asia, CSI e Australasia. Offre API nelle aree terapeutiche di antipertensivo, antimalarico, diuretico, DMARD e antielmintico. L'azienda fornisce anche formulazioni generiche e di marca nei segmenti terapeutici, tra cui allergia, farmaci antineoplastici/cancro, antiartritici, antiepilettici, antipertensivi, cardiologia, diabete, dermatologia, diabetologia, emollienti/protettivi, febbre, gastroenterologia, ematologia, elminti, epatoprotettivi, immunosoppressori, malattie infettive, malaria, neurologia, dolore neuropatico e FANS, oltre a nutraceutici, oftalmologia, farmaci orali contro il diabete, ortopedia, probiotici, psichiatria, respiratori, reumatologia e urologia.

Ipca Laboratories Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Ipca Laboratories con la sua capitalizzazione di mercato?
IPCALAB statistiche fondamentali
Capitalizzazione di mercato	₹397.48b
Guadagni(TTM)	₹6.61b
Ricavi(TTM)	₹84.98b

60.1x

Rapporto P/E

4.7x

Rapporto P/S

IPCALAB è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
IPCALAB Conto economico (TTM)
Ricavi	₹84.98b
Costo del fatturato	₹30.57b
Profitto lordo	₹54.41b
Altre spese	₹47.80b
Guadagni	₹6.61b

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	26.06
Margine lordo	64.03%
Margine di profitto netto	7.78%
Rapporto debito/patrimonio netto	14.2%

Come si è comportato IPCALAB nel lungo periodo?

Vedi performance storica e confronto

Dividendi

0.3%

Rendimento attuale del dividendo

15%

Rapporto di remunerazione

IPCALAB paga dividendi affidabili?

Vedere la storia dei dividendi e i benchmark di IPCALAB

Quando è necessario acquistare IPCALAB per ricevere un dividendo imminente?
Ipca Laboratories date dei dividendi
Data di stacco del dividendo	Nov 25 2024
Data di pagamento dei dividendi	Dec 10 2024
Giorni fino al dividendo Ex	6 days
Giorni prima della data di pagamento dei dividendi	21 days

IPCALAB paga dividendi affidabili?

Vedere la storia dei dividendi e i benchmark di IPCALAB

IPCALAB Panoramica delle azioni

Premi

Analisi del rischio

Ipca Laboratories Limited Concorrenti

NSEI:AJANTPHARM

₹360.8b

NSEI:GLAND

₹292.2b

BSE:500660

₹408.6b

BSE:506943

₹260.8b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Second quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Dividend of ₹2.00 announced

Ipca Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024

Ipca Laboratories Limited Announces Cessation of Manisha Premnath as Independent Director and Member of the Nomination & Remuneration Committee and Stakeholders Relationship Committee, Effective September 21, 2024

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Recent updates

Second quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Dividend of ₹2.00 announced

Ipca Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024

Ipca Laboratories Limited Announces Cessation of Manisha Premnath as Independent Director and Member of the Nomination & Remuneration Committee and Stakeholders Relationship Committee, Effective September 21, 2024

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Price target increased by 8.6% to ₹1,320

Ipca Laboratories Limited Approves Appointment of Vivek Shiralkar as an Independent Director

Upcoming dividend of ₹2.00 per share

Ipca Laboratories Limited to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Less than half of directors are independent

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Ipca Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Full year 2024 earnings released: EPS: ₹25.82 (vs ₹18.58 in FY 2023)

Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing

Ipca Laboratories Limited to Report Q4, 2024 Results on May 29, 2024

Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director

Price target increased by 9.1% to ₹1,097

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings

Ipca Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

CFO, MD & Executive Director recently sold ₹22m worth of stock

Price target increased by 9.7% to ₹987

Upcoming dividend of ₹2.00 per share at 0.2% yield

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited to Report Q2, 2024 Results on Nov 10, 2023

Ipca Laboratories Limited Appoints Hitesh Kumar Maheshwari as President R&D (Formulations)

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Ipca Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q4, 2023 Results on May 29, 2023

Price target decreased by 7.1% to ₹858

Investor sentiment deteriorates as stock falls 15%

Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet

Consensus EPS estimates fall by 21%

Third quarter 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Ipca Laboratories Limited (BSE:524494)acquired additional 6.53% stake in Trophic Wellness Pvt. Ltd. for INR 105.8 million.

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Ipca Laboratories Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on December 7, 2022

Ipca Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Insider recently sold ₹1.7m worth of stock

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Ipca Laboratories Limited Approves Interim Dividend as Final Dividend for Financial Year Ended 31St March, 2022

Now 20% undervalued

Ipca Laboratories Limited Announced Demise of Dev Parkash Yadava, Non-Executive and Independent Director

Ipca Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Now 20% undervalued after recent price drop

Full year 2022 earnings: EPS misses analyst expectations